1. Background
2. Objectives
3. Methods
3.1. Administration of the Drugs
3.2. Experimental Animal Groups
3.3. ECT Method
3.4. Behavioral Tests
3.5. Forced Swimming Test
3.6. Sucrose Preference Test
3.7. Open Field Test
3.8. Elevated Plus Maze Test
3.9. Assessment of Oxidative Stress Biomarkers
3.9.1. Malondialdehyde Assessment in the Prefrontal Cortex Area
3.9.2. Measurement of Superoxide Dismutase Activity in the Prefrontal Cortex
3.9.3. Prefrontal Cortex Assessment of Glutathione
3.9.4. Prefrontal BDNF Level Measurement
3.9.5. Histological Evaluation of the Prefrontal Cortex
3.10. Statistical Analysis
4. Results
4.1. FST Analysis
A, Immobility time; and B, sucrose preference test data in the control and treatment groups (bars show data as mean ± SEM; Abbreviations: Cont, control; ECT, electroconvulsive therapy; Hes, hesperetin; Res, reserpine; * and $ P < 0.05, respectively, show differences in the control and reserpine groups; n = 10 in each animal group).
4.2. SPT Results
4.3. OFT
A, The number of line crossings; and B, open arm entry percentage in open field and elevated plus maze tests (bars show the mean ± SEM data in each animal group; Abbreviations: Cont, control; ECT, electroconvulsive therapy; Hes, hesperetin; Res, reserpine; * P < 0.05, $ P < 0.05, and $$ P < 0.01 significantly indicated the difference between the mentioned bars and control and reserpine animals, respectively; # indicates a significance level vs Res + ECT, Hes (10 and 20 mg/kg), or ECT + Hes (10 mg/kg) groups; n = 10 in each animal group).
4.4. Obtained Data from EPMT
4.5. Oxidative Stress Biomarkers Data
Malondialdehyde, superoxide dismutase, and glutathione stress oxidative biomarkers data in the anterior prefrontal cortex of the experimental groups [bars show the mean ± SEM of values; Abbreviations: Cont, control; ECT, electroconvulsive therapy; Hes, hesperetin; Res, reserpine; *, **, and *** P < 0.05, 0.01, and 0.001 (difference with the control); $, $$, and $$$ P < 0.05, 0.01, and 0.001 vs reserpine; ## (1, 2) and ### (1, 2) P < 0.01 and 0.001 vs Res + Hes (10 and 20 mg/kg) and finally, &&& P < 0.001 vs Res + ECT group; n = 5 in each group].
3.6. Prefrontal Assessment of Prefrontal Cortex BDNF
Prefrontal brain-derived neurotrophic factor levels in the control and treatment animals [The bars indicate the mean ± SEM of data; Abbreviations: Cont, control; ECT, electroconvulsive therapy; Hes, hesperetin; Res, reserpine; * and *** P < 0.05 and 0.001 display the difference with the control. $, $$, $$$ show P < 0.05, 0.01, and 0.001 compared to the reserpine animals; ## P < 0.05 indicates a considerable difference compared to the Res + Hes (10 and 20 mg/kg), Res + ECT, and Res + ECT + Hes (10 mg/kg) groups; n = 5 in each group].
4.7. Neuronal Cell Death Assessment in the Prefrontal Cortex
The percentage of cell death in the prefrontal cortex in the control and treatment animals (Bars indicate the mean ± SEM of data; Abbreviations: Cont, control; ECT, electroconvulsive therapy; Hes, hesperetin; Res, reserpine; * and *** P < 0.05 and 0.001 compared to the control group; $$$ P < 0.001 with respect to the Res group; ## and ### P < 0.01 and 0.001 show the difference related to Res + Hes (10 and 20 mg/kg) and Res + ECT groups; n = 5 in each group).
Microscopic section of the prefrontal cortex, staining with the Nissl method for presentation of the number of cell death in the control and other treatment groups (the tip of the black arrow shows cell death numbers; Abbreviations: Cont, control; ECT, electroconvulsive therapy; Hes, hesperetin; Res, reserpine; n = 5 in each animal group).



![Malondialdehyde, superoxide dismutase, and glutathione stress oxidative biomarkers data in the anterior prefrontal cortex of the experimental groups [bars show the mean ± SEM of values; Abbreviations: Cont, control; ECT, electroconvulsive therapy; Hes, hesperetin; Res, reserpine; *, **, and *** P < 0.05, 0.01, and 0.001 (difference with the control); $, $$, and $$$ P < 0.05, 0.01, and 0.001 vs reserpine; ## (1, 2) and ### (1, 2) P < 0.01 and 0.001 vs Res + Hes (10 and 20 mg/kg) and finally, &&& P < 0.001 vs Res + ECT group; n = 5 in each group]. Malondialdehyde, superoxide dismutase, and glutathione stress oxidative biomarkers data in the anterior prefrontal cortex of the experimental groups [bars show the mean ± SEM of values; Abbreviations: Cont, control; ECT, electroconvulsive therapy; Hes, hesperetin; Res, reserpine; *, **, and *** P < 0.05, 0.01, and 0.001 (difference with the control); $, $$, and $$$ P < 0.05, 0.01, and 0.001 vs reserpine; ## (1, 2) and ### (1, 2) P < 0.01 and 0.001 vs Res + Hes (10 and 20 mg/kg) and finally, &&& P < 0.001 vs Res + ECT group; n = 5 in each group].](https://brieflands.com/journals/ijpbs/articles/122915/figures/ijpbs-122915-i004-F4-preview.webp)
![Prefrontal brain-derived neurotrophic factor levels in the control and treatment animals [The bars indicate the mean ± SEM of data; Abbreviations: Cont, control; ECT, electroconvulsive therapy; Hes, hesperetin; Res, reserpine; * and *** P < 0.05 and 0.001 display the difference with the control. $, $$, $$$ show P < 0.05, 0.01, and 0.001 compared to the reserpine animals; ## P < 0.05 indicates a considerable difference compared to the Res + Hes (10 and 20 mg/kg), Res + ECT, and Res + ECT + Hes (10 mg/kg) groups; n = 5 in each group]. Prefrontal brain-derived neurotrophic factor levels in the control and treatment animals [The bars indicate the mean ± SEM of data; Abbreviations: Cont, control; ECT, electroconvulsive therapy; Hes, hesperetin; Res, reserpine; * and *** P < 0.05 and 0.001 display the difference with the control. $, $$, $$$ show P < 0.05, 0.01, and 0.001 compared to the reserpine animals; ## P < 0.05 indicates a considerable difference compared to the Res + Hes (10 and 20 mg/kg), Res + ECT, and Res + ECT + Hes (10 mg/kg) groups; n = 5 in each group].](https://brieflands.com/journals/ijpbs/articles/122915/figures/ijpbs-122915-i005-F5-preview.webp)

